Regulatory Insights

61. 33 Questions To Ask Before Buying Data Management Software
    4/30/2013

    While choosing the wrong product is never a good idea, when it comes to clinical trials software, the wrong product could be disastrous for your company.

62. Interviewer: Questions To Ask During An Interview
    4/29/2013

    If you’re like me and most people I’ve talked to, interviewing on either side of the table can be a daunting and arduous task. By Peggy Berry, Pharma Interactive Training Courses, www.phitcourses.com

63. The Sunshine Act - It's Finally ‘Official’
    4/19/2013

    So now that the long wait is over for the final rule, where do you go from here? On February 8th, 2013 the final rule of the Physician Payment Sunshine Provision (PPSP aka "Sunshine Act") was released by The Centers for Medicare and Medicaid Services (CMS). By Kevin Williams

64. 5 Reasons To Synergize CTA Negotiations And Essential Document Collection
    4/19/2013

    The contractual and regulatory landscapes are ever-changing, increasingly complex and study timelines just keep getting shorter. By Rebecca Arch

65. Toxicometabolomics For Compound Attrition To Reduce Late Stage Failures Due To Safety
    4/10/2013

    Many ’omics’ technologies have now become the primary way of discovering new biomarkers, and validation of these biomarkers is a relatively new and evolving concept. By Michael V. Milburn, John A. Ryals, and Lining Guo

66. MHRA’s Summary Of PV Systems (SPS) Document
    3/26/2013

    As everyone who deals with the EU and the UK in drug safety knows, the EMA issued a new set of Good PV Guidelines to replace (largely) Volume 9A. By Bart Cobert

67. MHRA’s Compliance Report
    3/26/2013

    On February 5, 2013, the MHRA put out an update bulletin on its “Compliance Report”. The Compliance Report from the MHRA began around 2009 when they moved to a risk based pharmacovigilance (PV) inspection process. By Bart Cobert

68. Don’t Take It For Granted
    3/20/2013

    Investigator grant payments are typically the single greatest expense in a clinical trial budget, often accounting for 40 to 60 per cent of the total budget. By Kevin Williams, CFS Clinical

69. CFS Clinical Helps Top 20 Pharma Improve Investigator Payment And Budget Management While Addressing Sunshine & FMV Compliance
    3/19/2013

    Like its peers of all sizes operating in the United States, this Top 20 Pharma has faced the challenge of anticipating and addressing the Physician Payment Sunshine Provision (PPSP) within the Patient Protection and Affordable Care Act (PPACA) of 2009. Presented By Jim DiCesare, VP and General Manager, Contract and Regulatory Services

70. FDA Encourages More Women in Clinical Trials
    3/1/2013

    The FDA issued a draft guidance on the study and evaluation of gender differences in medical device clinical studies. The guidance is issued with hopes to increase the number of female subjects enrolled in clinical trials.